WAKIX (pitolisant), histamine H3 inverse agonist/antagonist

NEUROLOGY - New medicinal product

Opinions on drugs - Posted on Oct 14 2016

Inclusion

WAKIX has Marketing Authorisation in the treatment of adults with narcolepsy with or without cataplexy.
In a single short-term study, it reduced daytime sleepiness versus placebo without demonstrating non-inferiority versus modafinil.
Its efficacy on cataplexy, another characteristic symptom of narcolepsy, was only demonstrated short-term versus placebo in very severe patients.

Moderate

minor

Therapeutic use

Évaluation des médicaments

All our publications

My account